Puma Biotechnology price target lowered to $7 from $8 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Puma Biotechnology to $7 from $8 and keeps a Buy rating on the shares, citing a lower 2025 non-GAAP EPS estimate of 70c after the company reported Q4 U.S. Nerlynx sales that were negatively impacted by lower enrollments seen in Q3.